Radioimmunotherapy improves response in chemotherapy-refractory NHL

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2002年 / 16卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：253 / 254
页数：2
相关论文
共 50 条
  • [21] Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML
    Boehm, Alexandra
    Mayerhofer, Matthias
    Herndlhofer, Susanne
    Knoebl, Paul
    Sillaber, Christian
    Sperr, Wolfgang R.
    Jaeger, Ulrich
    Valent, Peter
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2009, 20 (08) : 775 - 778
  • [22] T-cell therapy for chemotherapy-refractory CMV infection.
    Einsele, H
    Rufer, N
    Roosnek, E
    Hebart, H
    Loeffler, J
    Grigoleit, U
    Kleihauer, A
    Bruemmendorf, T
    Riegler, S
    Jahn, G
    Sinzger, C
    Kanz, L
    BLOOD, 2000, 96 (11) : 478A - 478A
  • [23] Effect of preoperative concomitant chemoradiotherapy in chemotherapy-refractory breast cancer on feasibility of curative surgery and pathologic tumor response
    Ghorbel, I.
    Heymann, S.
    Delaloge, S.
    Belaid, A.
    Azoury, F.
    Mazouni, C.
    Balleyguier, C.
    Vielh, P.
    Marsiglia, H.
    Bourgier, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Current role of systemic therapy in transarterial chemotherapy-refractory hepatocellular carcinoma patients
    Kang, Hansung
    Lee, Hye Won
    INTERNATIONAL JOURNAL OF GASTROINTESTINAL INTERVENTION, 2021, 10 (04): : 183 - 188
  • [25] Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma
    Michael Bitzer
    Stephan Spahn
    Sepideh Babaei
    Marius Horger
    Stephan Singer
    Klaus Schulze-Osthoff
    Pavlos Missios
    Sergios Gatidis
    Dominik Nann
    Sven Mattern
    Veit Scheble
    Konstantin Nikolaou
    Sorin Armeanu-Ebinger
    Martin Schulze
    Christopher Schroeder
    Saskia Biskup
    Janina Beha
    Manfred Claassen
    Kristina Ruhm
    Antti Poso
    Nisar P. Malek
    npj Precision Oncology, 5
  • [26] Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
    Carvalho, Adriana Camargo
    Leal, Frederico
    Sasse, Andre Deeke
    PLOS ONE, 2017, 12 (04):
  • [27] Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma
    Bitzer, Michael
    Spahn, Stephan
    Babaei, Sepideh
    Horger, Marius
    Singer, Stephan
    Schulze-Osthoff, Klaus
    Missios, Pavlos
    Gatidis, Sergios
    Nann, Dominik
    Mattern, Sven
    Scheble, Veit
    Nikolaou, Konstantin
    Armeanu-Ebinger, Sorin
    Schulze, Martin
    Schroeder, Christopher
    Biskup, Saskia
    Beha, Janina
    Claassen, Manfred
    Ruhm, Kristina
    Poso, Antti
    Malek, Nisar P.
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [28] Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden
    Gbolahan, Olumide
    Hashemi-Sadraei, Neda
    O'Neil, Bert
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 644 - 648
  • [29] Helical tomotherapy for asymptomatic chemotherapy-refractory or -unfit multiple (3 or more) metastases
    Yamada, Yuki
    Shibamoto, Yuta
    Kishi, Kazushi
    Kita, Nozomi
    Kondo, Takuhito
    Murai, Taro
    Sugie, Chikao
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2022, 27 (01) : 125 - 133
  • [30] CISPLATIN AND MITOMYCIN-C IN ADVANCED CHEMOTHERAPY-REFRACTORY BREAST-CANCER
    CRIVELLARI, D
    GALLIGIONI, E
    FRUSTACI, S
    FOLADORE, S
    LORE, G
    MORASSUT, S
    MONFARDINI, S
    TUMORI, 1990, 76 (03) : 234 - 237
12345